Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.
Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, Tuck D, Harris L, Miller N, Slack F, Weidhaas J. Paranjape T, et al. Lancet Oncol. 2011 Apr;12(4):377-86. doi: 10.1016/S1470-2045(11)70044-4. Epub 2011 Mar 22. Lancet Oncol. 2011. PMID: 21435948 Free PMC article.
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. Ratner E, et al. Among authors: paranjape t. Cancer Res. 2010 Aug 15;70(16):6509-15. doi: 10.1158/0008-5472.CAN-10-0689. Epub 2010 Jul 20. Cancer Res. 2010. PMID: 20647319 Free PMC article.
Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk.
Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K, van den Ouweland A, Zelterman D, Slack FJ, Kidd KK, Weidhaas JB. Pelletier C, et al. Among authors: paranjape t. Cell Cycle. 2011 Jan 1;10(1):90-9. doi: 10.4161/cc.10.1.14359. Epub 2011 Jan 1. Cell Cycle. 2011. PMID: 21191178 Free PMC article.
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. Ratner ES, et al. Among authors: paranjape t. Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5. Oncogene. 2012. PMID: 22139083 Free PMC article.
Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.
McVeigh TP, Jung SY, Kerin MJ, Salzman DW, Nallur S, Nemec AA, Dookwah M, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, Pilarski R, Telesca D, Slack FJ, Weidhaas JB. McVeigh TP, et al. Among authors: paranjape t. Cell Cycle. 2015;14(13):2091-9. doi: 10.1080/15384101.2015.1041694. Epub 2015 May 11. Cell Cycle. 2015. PMID: 25961464 Free PMC article.
MicroRNAs: tools for cancer diagnostics.
Paranjape T, Slack FJ, Weidhaas JB. Paranjape T, et al. Gut. 2009 Nov;58(11):1546-54. doi: 10.1136/gut.2009.179531. Gut. 2009. PMID: 19834118 Free PMC article.
17 results